Semaglutide, marketed under Wegovy and Ozempic, belongs to a class of medications called GLP-1 agonists.
Understanding Semaglutide: From Development to Weight Loss Mechanisms
In 2005, the FDA approved the first GLP-1 agonist. The weight loss observed with these drugs was modest, but subsequent developments have significantly improved their efficacy. With time, GLP-1 agonists evolved and transitioned from daily to weekly injections, making the treatment more convenient and leading to the development of Semaglutide. The STEP-1 study, published in the New England Journal of Medicine, revealed that individuals could lose about 15% of their body weight and maintain this reduction. [1] It is particularly recommended for individuals with a Body Mass Index (BMI) of 30 or above, or those with a BMI of 27 and above who are also dealing with weight-related health issues like hypertension or type 2 diabetes.
The mechanisms behind Semaglutide’s effectiveness are multifaceted. Firstly, Semaglutide promotes a feeling of fullness or satiation by delaying the emptying of the stomach, which in turn activates stretch receptors signalling to the brain that one is full. This effect, coupled with its direct impact on the brain, enhances the sensation of satiety. Moreover, the drug can induce nausea and vomiting by stimulating specific receptors in the brain, which, while less desirable, contributes to its overall effect on reducing food intake.
Despite the side effects of nausea and vomiting, Semaglutide has shown promise for weight loss and managing type 2 diabetes by reducing blood glucose levels.
The Multifaceted Impact of Semaglutide on Weight Management
Semaglutide’s impact extends beyond calorie reduction. It influences eating habits, decreases the frequency of snacking, and reduces cravings for fast food and sugary snacks. These changes are not solely attributable to calorie restriction but result from the drug’s ability to control hunger, addressing the root cause of weight gain.
Challenges and Considerations in Using Semaglutide
Despite its effectiveness, the journey with Semaglutide is not without its challenges. Research published in the journal, Diabetes, Obesity, and Metabolism indicates a significant “rebound” effect, where most people tend to regain the weight they lost once they stop taking the medication. [2] This rebound is attributed to Semaglutide not addressing the underlying causes of weight gain nor preventing the metabolic adaptations that occur with weight loss. Consequently, experts emphasize the importance of incorporating long-term dietary and lifestyle changes to sustain weight loss.
The “Ozempic rebound” underscores a vital truth in weight management: medication can aid in weight loss but isn’t a standalone solution.
Combating the “Ozempic Rebound”: Strategies for Sustainable Weight Loss
Addressing the “Ozempic rebound” requires a multifaceted approach. While semaglutide offers a potent tool against obesity and diabetes, its optimal use period remains undefined. Individuals are encouraged to adopt significant lifestyle modifications, including diet, exercise, and medication, to mitigate weight regain. Obesity, being a chronic disease, may necessitate ongoing management, balancing the benefits of medication against potential risks, such as pancreatitis, kidney failure, and medullary thyroid cancer.
Preserving Muscle Mass While on Ozempic
Recent research indicates that Ozempic usage can decrease muscle mass. [3] However, the extent and clinical implications are still being debated. If you’re taking Ozempic, proactive steps can help preserve your muscle mass. Ensure you’re getting enough protein in your diet. Aim for 1 to 1.2 grams of protein per kilogram of body weight daily. Distribute your protein intake throughout the day. Regularly engage in resistance training or strength exercises. This type of training signals to your body that it needs to maintain and build muscle tissue.
Consult your doctor before starting medication or significantly changing your diet or exercise routine. Always discuss any health concerns with your healthcare provider.
References and Further Reading
- Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002.
- Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
- Bikou, A., et al. (2024). A systematic review of the effect of semaglutide on lean mass. Journal of Endocrinological Investigation, 47(5), 1083–1097.
Urdu 
English